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ABSTRACT
Objective: Obteinment and characterizing polymeric nanocapsules of simvastatin (SV), and investigating their action in an experimental model of 
peritoneal fibrosis induced in a rat by the infusion of peritoneal dialysis (PD) solution.
Methods: Poly (ε-caprolactone) nanocapsules containing SV (NC-SV) were prepared by interfacial deposition of a preformed polymer. A suspension of 
nanoparticles with no drug was prepared as negative control. The average particle size and polydispersity index were measured by photon correlation 
spectroscopy. The morphological and surface evaluation of prepared nanocapsules was performed using field emission scanning electron microscopy. 
The ultra-high performance liquid chromatography with photodiode array detection method was used to evaluate the drug encapsulation efficiency. 
The release profiles of SV from polymeric nanocapsules were obtained by dialysis diffusion technique. The Animal Study was performed in a total 
of 48 male Wistar rats (Rattus norvegicus) divided in four groups: Sham, PD group, SV group, and Simvastatin-loaded nanocapsules group (NC-SV). 
After 28 days, tissue samples were surgically removed from the abdominal to perform histological and immunohistochemistry analysis. The statistical 
analysis was performed by one-way ANOVA followed by Bonferroni test, or by Kruskal–Wallis.
Results: NC-SV presented suitable particle parameters with a mean particle size of 332 nm, and an encapsulation efficiency of 99.87±0.46%. The 
expression of tumor necrosis factor-alpha (TNF-α) was significantly different in NC-SV group.
Conclusion: SV-loaded nanocapsules for controlled drug delivery were suitably prepared. This nanoformulation remarkable decreased the TNF-α 
tissue expression even at low SV dose in a chronic PD model.
Keywords: Chronic renal insufficiency, Encapsulating peritonitis, HMG-CoA reductase inhibitor, Interleukin-6, Nanotechnology, Peritoneal fibrosis, 
Tumor necrosis factor-α.
INTRODUCTION
The prevalence of chronic kidney disease (CKD) is increasing worldwide 
and reached 2204 patients per million inhabitants in the USA. Peritoneal 
dialysis (PD) is a procedure used in 7.1% and 5% of patients on renal 
replacement therapy in the USA [1] and in Europe [2], respectively. The 
main obstacles to the long-term PD treatment are both infections and 
pathological changes in the peritoneal membrane exposed to dialysis 
solutions (DS), which affect 50% of PD patients. These patients may 
progress to the encapsulating peritonitis (EP) depending on the treatment 
time interval [3]. The risk of EP is significantly increased with PD treatment 
longer than 10 years (>10±12 years vs. >6±8 years, OR: 5.5). In addition, 
EP is a disease with high mortality, which reaches 74% in patients with 
severe forms [4]. It can also occur in children on PD, showing a similar 
prevalence to adults [5,6]. The symptoms onset may occur during PD. 
However, they may also occur very late, even after kidney transplantation 
[7,8]. In addition, when analyzing studies about the prevalence of EP, we 
have to take into account the diagnosis of this condition does not include 
a screening test to detect mild or asymptomatic cases, which explains 
the cases diagnosed years after the PD ending [9]. Therefore, the current 
prevalence of EP may be higher than that reported.
The pathophysiology of EP is complex. Factors that trigger the process 
are the exposure of peritoneal membrane to DS, bacterial infections, 
and inflammatory condition by uremia itself. Several mediators are 
involved, including cytokines [10]. Regardless of PD, uremia causes 
damage to the peritoneum. The carbonyl products formation occurs 
due to uremia, in addition to an accelerating production of advanced 
glycation end products. However, the PD onset also involves injury 
caused by catheter used and DS. This inflammatory condition could 
generate the peritoneum fibrosis and EP [11].
Simvastatin (SV) is a competitive reversible inhibitor of a natural 
substrate of hydroxymethylglutaryl coenzyme A reductase and the 
use of statins to prevent cardiovascular risk is well established. Its 
prescription depends on the analysis of cardiovascular risk of each 
patient. Patients with CKD are in the high-risk group; therefore, the 
prescription of statins is widely indicated to them [12]. Besides the 
lipid-lowering action, pleiotropic actions of statins have been described. 
These actions can contribute to a reduction of cardiovascular events 
in patients using statins. Statins inhibit the synthesis of isoprenoids, 
such as farnesyl pyrophosphate and geranyl pyrophosphate, also they 
inhibited the prenylation of specific proteins, such as Rho and Ras, 
which act through nuclear factor-κB (NF-κB), which is involved in the 
processes: Inflammation, proliferation and apoptosis, and it is implicated 
in atherogenesis. Statin treatment results in increased eNOS activity 
by reducing Rho prenylation. Statins also reduce the concentration of 
caveolin-1, which is the inhibitor partner of calmodulin and increases 
the affinity of binding of eNOS to calmodulin. Negative regulation of 
NF-κB pathway also leads to an increase in eNOS activity [13].
By these actions, statins have been used in several disease models, 
including their use in preventing peritoneal fibrosis. In a previous 
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study from our research group, Baroni et al. used the DS infusion model 
through daily puncture of the peritoneum to evaluate the influence of 
SV on fibrosis induced by DS in Wistar rats. Two groups of animals were 
subjected to a daily infusion of a 4.25% DS by intraperitoneal injection. 
One group received daily SV at a dose of 4 mg/kg, and the control group 
did not receive the drug. No effect was found on the use of SV, perhaps 
due to the low drug bioavailability [14].
Yeniçerioglu et al. studied the effect of atorvastatin in non-uremic Wistar 
rats. They were randomized in three groups: Sham (intraperitoneal 
saline), PD (PD 3.86% intraperitoneal dextrose-containing DS), and 
treatment (TX, 3.86% intraperitoneal dextrose containing DS plus 
atorvastatin added to drinking water at a dose of 80 mg/mL). The main 
findings were greater inflammation, fibrosis, and vascular proliferation 
in the PD group than in the Sham group. These features seemed to 
decrease significantly when atorvastatin was used as TX [15].
To evaluate the effect of SV on the mesenchymal epithelial transition 
action, Chang et al. carried one study in two parts. In vitro: Human 
peritoneal mesothelial cells (HPMCs) were exposed to 5.6 mmol/L 
glucose (NG) or 100 mmol/L glucose (HG) with or without SV at 
1 mmol/L concentration. In vivo: 32 Sprague-Dawley rats were 
submitted to PD catheters with saline (C, n=16) or 4.25% PD fluid (PD, 
n=16) for 4 weeks. SV intraperitoneally treatment (5 mg/kg/day) were 
applied to eight rats from each group. E-cadherin expression presented 
a significant decrease when compared to NG cells, while fibronectin 
expression, a-SMA, Snail were significantly increased in HPMCs 
submitted to HG, all these changes were repealed by SV (p<0.05) [16].
Yang et al. carried out a study in rats, comparing a group which used SV 
(10 mol/L) with a group without SV, divided in a subgroup that used 
troglitazone (50 mol/L) and one that did not. Cholesterol and oxidized LDL 
(ox-LDL) content was measured in macrophages. The content of IL-6 and 
tumor necrosis factor-alpha (TNF-α) in macrophages was measured, as 
well as the expression of IL-6 and TNF-α mRNA. It was demonstrated that 
macrophages exposed to ox-LDL had an increase in cholesterol content and 
foam cells appeared, an effect normally reversed by use of SV. The use of 
troglitazone abolished this effect [17]. Kim et al. showed that the presence 
of SV reduces the expression of IL-6 and IL-8 in an in vitro study, as well 
as reduces the expression of reactive oxygen species in cells isolated from 
intestinal cells stimulated by TNF-α. The same group, in a study model of 
intestinal ulceration in vivo, inducing lesions by anti-inflammatory drugs, 
demonstrated that the use of SV reduced the expression of reactive oxygen 
species, as well as the number of intestinal ulcerations [18].
None of papers briefly mentioned above used nanotechnology to 
optimize the drug effect. At present, one of the biggest challenges of the 
pharmaceutical industry is developing drugs with maximum of their 
therapeutic effect and reduction of their adverse effects [19], since 
approximately 40% of the discovered substances are left aside, mainly 
because of their low solubility and bioavailability [20]. To overcome 
these problems, the use of nanotechnology has altered the panorama of 
the pharmaceutical industries by enabling the development of safer and 
more effective drugs, with better biocompatibility and taking advantage 
of all their action potential [21].
SV is a lactone prodrug, which is modified in the liver. SV is a white, 
crystalline, and non-hygroscopic powder with log p=4.4. It is practically 
insoluble in water (30 μg/mL) and 0.1 mol/L HCl (60 μg/mL). Due to 
its very low aqueous solubility, SV exhibits controlled absorption by 
dissolution and, therefore, shows reduced absorption, distribution and 
arrival at the target organ. Various procedures can be used to improve 
SV solubility by enhancing its bioavailability as inclusion complex, 
solid dispersion, surfactant solubilization, and particle reduction 
techniques [22]. Therefore, nanotechnology can significantly improve 
the drug effects by creating new SV-loaded formulations.
The objective of this study was to develop and characterize SV-loaded 
nanocapsules and compare with pure drug and its effect on peritoneal 
fibrosis and on expression of TNF-α and IL-6 induced by the use of 
4.25% DS.
METHODS
Preparation of polymeric nanocapsules
Poly (ε-caprolactone) (PCL) nanocapsules containing simvastatin 
(NC-SV) were prepared by interfacial deposition of a preformed 
polymer [23]. Briefly, 100 mg of PCL (Mw 14,000 g/mol, Sigma-Aldrich, 
St. Louis, MO, USA) was solvated in acetone (27 mL) in the presence 
of sorbitan monostearate (Span® 60, 77 mg), triglycerides of capric/
caprylic acids (MCT, 300 mg), and SV (SV, 200 mg, Mw 418.57 g/mol, lot 
DK40-1506061, certified by Galena Farmacêutica, Campinas, Brazil). 
This organic phase was then dripped slowly into the aqueous phase 
containing water (53 mL) and polysorbate 80 (Tween® 80, 77 mg), 
previously prepared and maintained under vigorous magnetic stirring 
at 40°C. The magnetic stirring was kept for another 10 min after the 
end of the dripping and the solvent was eliminated using a rotary 
evaporator (FISATOM, model 801, Diadema, Brazil), reaching a final 
volume of 10 mL and drug concentration of 20 mg/mL. This formulation 
was obtained in triplicate from three different batches. A suspension of 
nanoparticles with no drug (NC-N) was prepared as negative control.
Characterization of polymeric nanocapsules
The average particle size and polydispersity index (PDI) (n=3) were 
measured by photon correlation spectroscopy (Zetasizer Nanoseries, 
Malvern Instruments, Malvern, UK) after diluting each sample in 
ultrapure water (1:500, v/v). At the same equipment and using the 
same sample preparation, zeta potential (n=3) was determined by 
electrophoretic mobility technique.
The morphological and surface evaluation of prepared nanocapsules 
was performed using field emission scanning electron microscopy 
(FESEM) (Tescan, model Mira 3, Brno, Czech Republic). The samples 
were previously submitted to metallization with gold in an IC-50 Ion 
Coater metallizer (Shimadzu, Kyoto, Japan). An acceleration voltage of 
8–10 kV was used to obtain electromicrographs.
The ultra-high performance liquid chromatography with photodiode 
array detection (UHPLC-DAD) method was used for evaluate the 
drug encapsulation efficiency using a previously validated analytical 
method [24] with modifications. In brief, suspension of nanocapsules 
was submitted to a combined ultrafiltration/centrifugation using 
centrifugal devices (Amicon® 10,000 NMWL, Millipore, Bedford, MA, 
USA) at 2200 g during 30 min in triplicate. Free SV was determined 
in ultrafiltrate using an UHPLC method in Nexera X2 equipment 
(Shimadzu, Kyoto, Japan). The UHPLC system was equipped with a 
column oven compartment (model CTO-20AC), an on-line degasser 
(model DGU-20A5RA), a quaternary pump (model LC-30AD), an auto 
sampler (model SIL-30 AC), a communication bus module (model 
CBM-20A), and a photodiode array wavelength detector (model SPD-
M20A). Data acquisition, analysis, and reporting were performed using 
LabSolutions® chromatography software (Shimadzu, Milton Keynes, 
UK, version 5.73). Chromatographic separation was accomplished using 
a Shimadzu Shim-pack XR-ODS III C18 analytical column (Kyoto, Japan) 
with 2.2 μm particle size, 2.0 mm internal diameter at temperature 
of 40±2°C using UV detection at 237 nm. The isocratic mobile phase 
consisted of acetonitrile: water acidified with phosphoric acid (83:17, 
v/v) at a flow rate of 0.75 mL/min. The encapsulation efficiency (EE, %) 





In vitro drug release study
The release profiles of SV from polymeric nanocapsules were obtained 
by dialysis diffusion technique. Each sample (30% ethanol-water 
solution of SV and NC-SV) was placed into a dialysis bag (Spectra/
Por® molecular porous membrane tubing, MWCO 10,000, Spectrum 
Fig. 2: UHPLC-DAD chromatograms obtained for simvastatin-
loaded (a) and non-loaded (b) nanocapsules. Chromatographic 
conditions:isocratic elution mode; mobile phase: 
acetonitrile:water acidified with phosphoric acid (pH 3.0) (83:17, 
v/v); flow rate: 0.75 mL/min; UV detection wavelength: 237 nm; 
column temperature: 40±2°C; run time: 2.11 min; and retention 
time: 1.71 min
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Laboratories, Rancho Dominguez, CA, USA) at an equivalent 
concentration of 1 mg/mL and a final volume of 3 mL. This system was 
then immersed in 500 mL of water with 30% of ethanol at 37°C and 
kept under continuous magnetic stirring of 50 rpm. Aliquots of 5 mL 
were withdrawn at predetermined time intervals and replaced by the 
same volume of fresh medium. The amount of SV released was assayed 
by the aforementioned UHPLC-DAD method. The experiment was 
performed in triplicate from three independent batches.
Animal study
The in vivo study was submitted to the Animal Ethics Committee from 
State University of Ponta Grossa (UEPG) and approved under number 
37/2018. A total of 48 male Wistar rats (Rattus norvegicus) weighting 
from 200 to 250 g were obtained from the Animal House Facility at the 
UEPG, Faculty of Medicine. The animals were fed a standard rat pellet 
diet and it was allowed free access to water. The rats were kept in 
labeled cages with a maximum of five animals per cage at 25±2°C and 
12-h light/dark cycle.
The intraperitoneal injection model was performed for induction of 
peritoneal fibrosis. A DS with glucose at 4.25% buffered with lactate 
(Baxter Hospitalar, São Paulo, Brazil) was intraperitoneally injected 
using a 25 × 7/8” needle. There were four experimental groups, divided 
as follows: Group 1 (Sham), 12 animals submitted to the daily repeated 
puncture for 28 days with no solution infusion; Group 2 (PD group), 12 
animals subjected to the daily peritoneal puncture for 28 days with DS 
infusion at a dose of 10 mL/100 g of weight; and Group 3 (SV group), 12 
animals submitted to the daily repeated puncture for 28 days with DS 
infusion at 10 mL/100 g of animal weight. This group also received 4 mg/
kg of SV per gavage daily during 28 days. Group 4 (SV-loaded nanocapsules 
group – NC-SV), 12 animals submitted to the daily peritoneal puncture for 
28 days with DS infusion at 10 mL/100 g of weight. This group received 
NC-SV containing 4 mg/kg of SV per gavage daily.
After 28 days, the animals were slaughtered and 1-cm2 tissue samples 
were surgically removed from the abdominal wall of the upper right 
quadrant as far as possible from the puncture point. After the routine 
paraffin embedding, 4-μm thick sections were stained with hematoxylin 
and eosin and Sirius red (SR). Ten histological fields were chosen and 
ten peritoneum thickness measurements were taken in each field using 
the Axio Scan.Z1 digital slide scanner (Carl Zeiss Microscopy, Jena, 
Germany). The amount of collagen types I and III, in percentage per high 
power field (HPF), was automatically measured using SR staining with 
the Axio Scope.A1 polarized light microscope (Carl Zeiss Microscopy, 
Jena, Germany).
For immunohistochemistry, the 4-μm thick sections were rehydrated 
in decreasing ethanol concentration and incubated in 5% hydrogen 
peroxide and methanol. These samples were then immersed in 
ImmunnoRetrivier® (Dako, Carpinteria, CA, USA), followed by incubation 
in diluted solution of antibodies anti-TNF-α (ab6671, 1:100, Abcam®, 
Cambridge, UK) and anti-IL-6 (ab9324, 1:400, Abcam®, Cambridge, UK) 
at 4ºC. Then, the reaction was carried out using 3-3’-diaminobenzidine 
chromogen solution (code D7679, Sigma-Aldrich, St. Louis, MO, USA), 
followed by the staining with Harris’ hematoxylin solution (Biotec, 
Lages, Brazil), the ethanol dehydration process, and the clearing using 
xylene. The slides were observed using the Axio Scan.Z1 digital slide 
scanner and the ZEN 2.3 program (Carl Zeiss Microscopy, Göttingen, 
Germany) concerning to the presence/absence of TNF-α and IL-
6inpercentage per HPF of peritoneal samples.
The statistical analysis was performed by one-way ANOVA, followed by 
Bonferroni test, except for results of TNF-α, in which the Kruskal–Wallis 
test was used. p<0.05 was considered statistically significant.
RESULTS
Preparation and characterization of polymeric nanocapsules
SV-loaded PCL nanocapsules (NC-SV) and non-loaded PCL nanocapsules 
(NC-N) suspensions showed a uniform milky white appearance and 
atypical opalescent bluish reflection. NC-SV presented suitable particle 
parameters for oral use as mean particle size of 332 nm, PDI of 0.290, 
and zeta potential of –58.7 mV.
Nanoscale dimensions were registered for NC-SV (a) and NC-N (b) when 
their images were assessed by FESEM (Fig. 1). NCs were spherically 
shaped and had smooth surface with uniform distribution. In addition, 
no drug crystals were seen on their surfaces.
The proposed UHPLC-DAD method was used for determining the drug-
loading efficiency. Fig. 2 depicts the chromatograms obtained for SV-
loaded (a) and non-loaded (b) nanocapsules. SV showed an appropriate 
separation at short retention time of 1.71 min.
Comparing both chromatograms, the other formulation components 
demonstrated no interference in drug quantification. Considering all the 
chromatographic data, a high encapsulation efficiency of 99.87±0.46% 
was achieved for NC-SV.
In vitro drug release study
The SV release profiles as pure drug and nanoformulation (NC-SV) are 
reported in Fig. 3. The free SV showed a rapid drug release profile by 
reaching a mean release value of 80% after 148 min of the experiment. 
Fig. 1: Photomicrographs of simvastatin-loaded and non-loaded 
nanocapsules observed by FESEM: (a) NC-SV 
 (68 k× magnification) and (b) NC-N (82 k× magnification)
ba
Fig. 3: In vitro drug release profiles of free simvastatin (SV) and 
simvastatin-loaded nanocapsules (NC-SV) using 30% ethanol-
water solution as dissolution medium
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The NC-SV formulation released 80% SV at 2880 min (48 h). Therefore, 
the SV-loaded nanocapsules demonstrated a prolonged release profile 
with no burst effect, when compared with pure drug.
Animal study
The results of histological analysis are summarized in Table 1. 
In brief, no statistically significant difference was observed for 
peritoneal thickness when experimental groups were compared. 
However, a significant increase in the inflammation-associated 
collagen type III was achieved for PD group (p<0.001) when 
compared with Sham group. The SV group also presented a statistical 
difference in collagen type III expression comparing with Sham 
group (p<0.001), while the effect of NC-SV concerning to collagen 
type III was statistically similar (p>0.05) to the Sham group. The 
nanoformulation also revealed a statistical difference in collagen 
type III when compared with other experimental groups, PD group 
(p<0.001) and SV group (p<0.05). The same statistical significance 
was obtained to a usual collagen type I considering the studied 
groups due to its complementary nature in total collagen amount 
to reach 100%.
The results of TNF-α tissue expression in the peritoneal samples are 
depicted in Fig. 4. The TNF-α tissue expression was 23.5±14.5%, 
20.3±11.1%, and 0.79±0.76% (HPF) for PD and SV an NC-SV groups, 
respectively.
No statistical difference was observed between PD and SV groups. 
However, a statistically significant decrease in TNF-α tissue expression 
was achieved when NC-SV group was compared with PD (p<0.0002) 
and SV (p<0.0002) groups.
The immunohistochemical images for TNF-α expression in the 
peritoneal tissue of rats are shown in Fig. 5. TNF-α immunoslides 
indicated that the TNF-α protein expression (%/HPF) was significantly 
higher in the peritoneal section obtained from PD and SV groups 
(Fig. 5a and b). Nanoformulation treatment containing simvastatin 
(NC-SV group) prevented the increase in peritoneal tissue expression 
of TNF-α (Fig. 5c).
Concerting to the IL-6, the tissue expression was 3.14±1.35%, 
2.72±1.28%, and 2.62±1.32% (HPF) for PD, SV, and NC-SV groups, 
respectively. No statistically significant difference was observed 
between paired groups.
DISCUSSION
In this study, SV-loaded nanocapsules were successfully obtained as 
nanosuspensions by the interfacial deposition of preformed polymer. 
This formulation presented a final opalescent bluish aspect due to the 
Tyndall effect from colloids [23,25]. The mean particle size and PDI 
value were similar to those previously recorded by photon correlation 
spectroscopy for other polymeric nanocapsules [26]. PDI values close 
to zero are considered monodisperse and >0.5 indicate heterogeneous 
dispersion [23]. Zeta potential was also suitable since it was higher 
than |30 mV|, which is usually considered having sufficient repulsive 
force to achieve better physical colloidal stability [25]. The electron 
micrographs confirmed the spherical shape and the smooth surface, 
which are typical to polymeric nanocapsules, obtained using PCL as 
polymer [27]. Hence, the nanoformulation containing SV showed all 
required features in terms of size, superficial charge, and morphology 
for its use by oral, intraperitoneal, and intravenous routes.
However, it is essential to investigate the encapsulation efficiency to 
discover the total drug entrapped within the colloidal nanoformulation 
after its preparation and to use corresponding drug amount in animal 
studies. SV-loaded PCL nanocapsules (NC-SV) had encapsulation 
efficiency near to 100%. This result is better than that one made by 
Gambhire et al., who obtained SV-loaded solid lipid nanoparticles by 
pre-emulsion followed by the ultrasonication with an encapsulation 
efficiency of 72.52% [28]. It was also slightly better than the result 
achieved by Zhang et al., who prepared lipid nanoparticles by emulsion-
solvent evaporation and achieved encapsulation efficiencies from 
97.2% to 99.2% [29]. Shinde and More studied poly (lactic-co-glycolic 
acid) nanoparticles obtained by nanoprecipitation and recorded 
encapsulation efficiencies between 87.03% and 97.18% [30]. These 
high values of encapsulation efficiency are mainly due to the poor 
aqueous solubility of SV, which provides a high drug entrapment in oil/
lipid-based formulations [29].
The next stage was to investigate the in vitro drug release in order to 
confirm if nanoformulation could provide a controlled-release pattern. 
A typical structure of an oily core surrounded by a polymeric shell was 
strategically planned for this purpose to avoid the immediate release 
of SV and to obtain a prolonged response. This approach was crucial 
to avoid the administration of multiple doses per day on rats and 
ensuring a longer-lasting pharmacological effect than free drug. Our 
nanoformulation containing SV proved a prolonged release of the drug 
during 48 h with no relevant initial burst. Fathi et al. [31] prepared lipid 
nanoparticles through emulsification-solvent evaporation followed by 
ultrasonication and reported an initial rapid release of SV using dialysis-
spectrophotometry, which was proportional to the oleic acid and the 
surfactant content, followed by a prolonged release for 24 h. Therefore, 
the formulation NC-SV can provide a controlled-release pattern for SV 
Table 1: Peritoneum thickness and collagen amount in the 
experimental groups submitted to the chronic use of 4.25% DS 
for 28 days
Parameters Experimental groups
SHAM PD SV NC-SV
Thickness* (µm) 19.1±6.0 20.1±4.9 19.2±6.1 25.5±9.1
Collagen type I* 
(%/HPF)
82.9±7.8 77.2±12.4 56.8±13.6 79.6±8.1
Collagen type III* 
(%/HPF)
17.1±7.8 22.8±12.4 43.2±13.6 20.4±8.1
Collagen ratio  
type I: III 
4.85:1 3.38:1 1.31:1 3.96:1
Increase in 








*Values are depicted as mean±standard deviation, **Significant differences 
occur in the Collagen I: III ratio in Group SV when compared to the others. DS: 
Dialysis solutions, PD: Peritoneal dialysis, SV: Simvastatin, NC-SV: Nanocapsules 
















p < 0.0002 Kruskal Wallys 
PD SV
Fig. 4: Tumor necrosis factor-alpha (TNF-α) tissue expression (percentage per high power field) in the peritoneal samples of rats treated 
with peritoneal dialysis solutions (PD), simvastatin (SV), and simvastatin-loaded nanocapsules (NC-SV)
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and can ensure a better pharmacokinetics since this nanocarrier can 
also avoid the SV extensive metabolism by cytochrome-3A system in gut 
and liver [29].
Regarding to the animal study, SV and NC-SV groups did not decrease 
the peritoneum thickness as expected. These results may be associated 
with the low dose of SV used (only 4 mg/kg) as free drug and in the 
SV-loaded nanocapsules. Rats can support very high doses of SV [32]. 
Besides that, a previous animal study involving the administration of SV 
at 25 mg/kg did not observe changes in bone tissue, after ovariectomy, 
or in bone healing of rats [33]. However, the use of atorvastatin added 
into drinking water at a dose of 80 mg/mL provided significant minor 
fibrosis and thinner peritoneum [15]. In general, Wistar rats usually 
drink 20–50 mL water a day (10 mL/100 g body weight/day) [34]. 
Hence, high doses of atorvastatin reaching above 1.6 g/day were used 
for achieving morphological changes in peritoneum thickness of rats. In 
this sense, we assume that low dose of SV used was accountable for the 
lack of effects on the peritoneal thickness of Wistar rats in the SV and 
NC-SV groups.
When the type of collagen was evaluated, the NC-SV group showed 
an expression of type III collagen statistically similar to sham and 
DP. Therefore, nanoformulation was able to reduce type III collagen 
associated with inflammation in order to control levels. Type III 
collagen is secreted by fibroblasts and other types of mesenchymal 
cells, making it an important element in several diseases associated 
with inflammation, such as renal fibrosis [35]. Consequently, the 
low expression of type III collagen provides strong evidence that 
inflammation has been significantly suppressed by nanoformulation, 
which was not so remarkable with the use of free SV, although the 
anti-inflammatory effect of SV is well known to inhibit formation of 
intracellular isoprenoids and improve the bioavailability of NO [12].
The reason of DP group was not significantly different from the sham 
which is not very clear. One possible explanation is due to the different 
manipulation between these groups, since the sham group was not 
subjected to gavage. It is known that damage to the esophageal mucosa 
caused by gavage can alter the cells of intestinal epithelium. The damage 
of esophageal epithelium causes a reduction in γδ T cells, which, in 
turn, plays an important regulatory role in maintaining the function of 
intestinal epithelium barrier and its cell renewal. The reduction in γδ T 
cells can also cause a reduction in CD3+ cells. This study provides initial 
evidence of the importance of esophageal integrity and intestinal cell 
populations and that the use of prolonged and repeated gavage can be 
accompanied by immunological complications [36].
Recently, it has been discovered that not only do these γδ T cells provide 
essential epithelial growth factors, which are crucial for maintaining 
tissue homeostasis and timely return to steady-state after damage, 
but they also act quickly to compartmentalize and limit microbial 
pathogenic exposure to the systemic immune compartment [37]. We 
can hypothesize that animals submitted to repeated gavage may have 
had a more intense inflammatory reaction. Anyway, in the NC-SV 
group, which was also subjected to gavage, the pattern of proportion 
between types I and III collagen was similar to that of sham. This could 
be explained by the more intense anti-inflammatory action of this 
formulation.
Considering the promising results obtained for the NC-SV group during 
the collagen analysis, the investigation was deepened to verify which 
inflammatory cytokines was inhibited. The nanoformulation decreased 
expressively the TNF-α level expression in peritoneal tissue of rats, 
what was not observed for free SV. TNF-α plays a key role in many 
inflammatory diseases. It is produced by macrophages, natural killer 
cells, neutrophils, and several non-hematopoietic cells. Although TNF-α 
was initially identified by its cytotoxicity against certain cell lines, its 
primary function (associated with IL-1) is to initiate the cascade of 
factors associated with inflammatory response. Therefore, it seems 
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TNF-α and IL-6, was observed in other animal study involving intestinal 
ischemia in rats and SV at a dose of 20 mg/kg [39]. In that sense, the 
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precipitate indicates the presence of the target antigen. TNF-α 
level was high in the peritoneal tissue slices of peritoneal dialysis 
rats (a), markedly present in the peritoneal tissue of simvastatin 
group (b), but not in rats treated with NC-SV (c). Several 
microphotographs were taken using a ×10–100 magnification 
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of TNF-α expression when the experimental rat model of peritoneal 
fibrosis induced by infusion of PD solution was used.
Considering the reduction of IL-6 by SV in vascular smooth muscle 
cells and macrophages was previously reported [37], this cytokine 
expression was also investigated. However, IL-6 levels were similar 
among the PD, SV, and NC-SV groups. Kishimoto [41] proposed that 
IL-6 is a multifunctional cytokine involved in cell proliferation and 
differentiation, maintaining immune homeostasis, macrophage 
function, and other key functions. IL-6, acting through the latent 
transcription factors signal transducer and activator of transcription-3 
(STAT3) and STAT1, also plays pivotal roles in governing leukocyte 
infiltration during acute inflammation [42]. In this present study, no 
significant change in the IL-6 tissue expression was found for pure 
SV and SV-loaded nanoformulation. The possible reason may be that 
IL-6 is an acute pro-inflammatory mediator and the animal model 
involved the chronic and long-lasting use of 4.25% DS. In general, the 
detection of IL-6 occurs in studies performed during few days [40], but 
this inflammatory stimulus was kept for almost 1 month in the present 
study.
CONCLUSION
SV-loaded nanocapsules for controlled drug delivery were 
suitably prepared. This nanoformulation remarkable decrease the 
inflammation-associated collagen type III and the TNF-α tissue 
expression even at low SV dose in a chronic PD model and may be 
further investigated as a nanotechnology-based approach for treating 
peritoneal fibrosis or even EP.
We can also corroborate with Alston et al. considerations that EP is 
a condition related to several pathological processes that lead to the 
appearance of adhesion, fibrosis, vasculopathy, and the formation 
of encapsulated tissue on the injured peritoneal surface [43]. EP 
can represent a multidimensional pathological process and novel 
therapeutic approaches need to be proposed.
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